Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
05/31/2013
Trade Name:
Bloxiverz
Generic Name or Proper Name (*):
neostigmine methylsulfate
Indications Studied:
Reversal of the effects of non-depolarizing neuromuscular-blocking agents after surgery
Label Changes Summary:
Approved for use in pediatric patients of all ages The evidence for efficacy of neostigmine is derived from the published literature Recovery of neuromuscular activity occurs more rapidly with smaller doses of cholinesterase inhibitors in infants and children than in adults. However, infants and small children may be at greater risk of complications from incomplete reversal of neuromuscular blockade due to decreased respiratory reserve. The risks associated with incomplete reversal outweigh any risk from giving higher doses of neostigmine Since the blood pressure in pediatric patients, particularly infants and neonates is sensitive to changes in heart rate, the effects of an anticholinergic agent (e.g., atropine) should be observed prior to administration of neostigmine to lessen the probability of bradycardia and hypotension Information on dose, and pk New drug
Product Labeling:
Labeling
PREA(P):
P
Sponsor:
Eclat Pharmaceuticals, LLC
NNPS:
FALSE'
Therapeutic Category:
Neuromuscular blockade reversal
-
-